Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
A new crop of companies is lining up to buy patient data from hospitals and sell it to those wanting to train AI or do ...
As the health care sector embraces AI, the incoming administration confronts some pressing challenges about what to regulate, ...
After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
By 2037, the U.S. may be short 187,000 doctors. Nicole C. McCann and Rochelle P. Walensky propose one way to start addressing ...
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
A proposed FDA rule would set nicotine levels on tobacco products at less than half the current average and could save ...
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
An international group of experts proposes two new categories of disease: preclinical and clinical obesity and the FDA ...
The FDA has banned a red food dye that has long been on the enemies list of consumer groups, as well as the designated next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback